$GYRE

2 stories mentioning GYREUpdated 45d ago

Every FINWIRES story that references GYRE, newest first.

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE

Wire53d ago

Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen

Gyre Therapeutics (GYRE) said Monday it closed the purchase of clinical-stage biopharmaceutical firm Cullgen through an all-stock transaction valued at roughly $300 million.The deal turns the acquired business into a wholly owned unit focusing on therapies for fibrosis and inflammatory diseases, the company said.Former Cullgen chief executive Ying Luo was appointed president, chief executive, and board member of the combined organization, while Ping Zhang will maintain his position as chairman of the board, Gyre Therapeutics said.Price: $7.97, Change: $+0.17, Percent Change: +2.18%

$GYRE

Track with the FINWIRES app suite

FolioX

Track GYRE in your portfolio

WheelAI

Analyze GYRE options with the wheel strategy

StockInsider

See market sentiment on GYRE